Prenatal Health News
-
Editas Medicine Announces Positive Initial EDIT-301 Safety And Efficacy Data From The First Four Patients Treated In The RUBY Trial And The First Patient Treated In The EdiTHAL Trial
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced positive initial safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY trial and from the first transfusion-dependent beta thalassemia patient treated in the EdiTHAL trial. The RUBY trial data will be presented in an oral presentation at ...
-
Medis Strain algorithms integrated in FetalHQ
MedisStrain Algorithms Integrated infetalHQ Our Strain algorithms are integrated in thefetalHQ imaging tool which is available on Voluson™ Expert 22 from GE Healthcare.fetalHQ allows users to make an easy and comprehensive evaluation of the size, shape, and contractility of the fetal heart to make more informed decisions about maternal/ fetal well-being and delivery planning using ...
-
Full-Scale PROTAC In Vivo Evaluation Services to Facilitate PROTAC Drug R&D
In the process of drug development, the evaluation of drug effectiveness is one of the keys to determining whether prodrugs can sufficiently reach the market stage. BOC Sciences, as a professional contract research organization, can take care of the PROTAC in vivo evaluation workload for clients with a transparent project process and comprehensive evaluation reports to facilitate their PROTAC ...
By BOC Sciences
-
BillionToOne Launches Novel Fetal Antigen NIPT as Part of UNITY Screen
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...
-
FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
LYTGOBI (pronounced “light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. The other approved FGFR inhibitors are reversible ATP-competitive inhibitors. LYTGOBI previously received breakthrough, orphan drug ...
-
What is IPL laser?
IPL photorejuvenation treatment is currently the most advanced high-tech beauty program, and it is also the safest and most effective beauty program. Then the theme of price and cost performance that everyone is concerned about, I will give you a comprehensive analysis! Bvlaser Bestview is commercial IPL machine supplier, we have professional IPL machine for sale. What is IPL photorejuvenation? ...
-
MindChild Medical, Inc. Announces FDA Clearance for M110 Monitor
(BusinessWire, North Andover, Massachusetts), MindChild Medical, Inc. today announced that it has received clearance for its Pre-Marketing Notification (510(k)) from the US Food and Drug Administration (FDA) for its MERIDIAN™ M110 non-invasive fetal heart monitor. MindChild anticipates entering the US market with MERIDIAN now that it has received the FDA clearance. ...
-
Sydney MedTech Baymatob completes capital raise to advance life-saving labour monitoring device
Sydney medical device company Baymatob has completed a placement of $4.215 million, with proceeds used to continue in-human clinical trials for its AI-guided labour monitoring device, Oli. Cornerstoned by Australian Unity’s Future of Healthcare Fund, the placement was strongly supported by Australian institutional and high net worth investors, securing long-term capital partners to support ...
-
Santa Barbara Cottage Hospital Enhances Maternal and Fetal Safety with Go-Live of PeriGen’s PeriWatch Vigilance
PeriGen®, an innovator in perinatal early warning systems, today announced that Santa Barbara Cottage Hospital, a 519-bed acute care teaching hospital and trauma center that is part of the not-for-profit Cottage Health system, is now using PeriGen’s PeriWatch Vigilance® automated maternal-fetal early warning system (EWS) in its labor and delivery (L&D) department. Founded in ...
-
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
The Companies are collaborating on an orderly transition through first half of 2022 while Sangamo explores options to advance the program, including seeking a new partner Phase 1/2 PRECIZN-1 study of investigational SAR445136 expected to be completed as planned; final patients in study expected to be dosed in third quarter of 2022 Preliminary proof-of-concept data presented at ASH 2021 showed ...
-
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
No adverse events related to investigational SAR445136 were reported All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood transfusions post engraftment Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 ...
-
PeriGen Deploys Mobile Version of PeriWatch Vigilance to Further Protect Moms and Babies During Childbirth
PeriGen Inc., the market leader in applying artificial intelligence (AI) to improve safety in childbirth, today introduced PeriWatch Vigilance® Mobile, a full-function browser-based solution providing access to its early warning system (EWS) and clinical decision support tool. By providing remote access to the full range of conditions monitored by PeriWatch Vigilance, the new solution ...
-
SCL Health to Deploy System-Wide OB Hub Powered by PeriWatch Command Center
PeriGen Inc., the market leader in applying artificial intelligence (AI) to improve safety in childbirth, today announced that SCL Health, a health system operating eight hospitals and 150 clinics in Colorado and Montana, is launching a centralized SCL Health OB Hub utilizing PeriGen’s PeriWatch Command Center enterprise-wide telehealth-platform. Through the OB Hub, a dedicated team of ...
-
MindChild Medical, Inc. Announces Gates Funded UNC LABOR Study Enrolls 6,000th Subject Recorded with Meridian™ Fetal ECG Research Device
The Meridian Fetal Research Device Accurately Extracts Fetal ECG to Enable Analytics on Fetal ECG Morphology, Heart Rate, Heart Rate Variability and Uterine Activity Using Surface Electrodes (North Andover, Massachusetts), Mindchild Medical, Inc. announced that the LABOR study recorded its 6,000th subject with MindChild’s Meridian Fetal Research Device. Jay Ward, MindChild Medical’s ...
-
Study Finds K2 Infant® Software Halves Poor Birth Outcomes At Australia’S Largest Maternity Service
04 August, 2021, Plymouth, UK: K2 Medical Systems (K2), a UK-based company providing specialised maternity software solutions and business unit of Harris, welcomes the publication of a paper detailing a recent study undertaken at Mater Mothers’ hospital Brisbane, Australia using the K2 INFANT-Guardian® (INFANT) system. (https://www.k2ms.com/blog/2020/mater-mothers-infant-paper.aspx) ...
-
InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, today announced the publication of the first-in-human comprehensive immunohistochemical evaluation of adult tendon repair following the local injection of fresh, uncultured, unmodified, autologous, adipose derived regenerative cells (UA-ADRCs). This newly-released research paper, titled “First ...
-
Seventh Sense Blood Collection Technology Key Part of Gateway Genomics’ SneakPeek Snap for Gender DNA Test
Making blood collection simpler, more convenient, and more comfortable. That’s our mission, and we are thrilled to share that our partner, Gateway Genomics, is leveraging our TAP II blood collection technology in its product offering, the SneakPeek Early Gender DNA Test. Called SneakPeek Snap, the blood collection device is included as part of the SneakPeek at-home blood collection kit. ...
-
Texas Children’s Pavilion for Women Teams up With PeriGen to Bring PeriWatch Vigilance® to Malawi
Texas Children’s Pavilion for Women® announced today the launch of the PeriWatch Vigilance® program in Lilongwe, Malawi (in southern Africa), in partnership with PeriGen Advanced Perinatal Software, a provider of innovative software solutions for over 20 years with a mission to protect mothers and babies everywhere. In a public-private partnership with the Texas Children’s ...
-
Perinatal Safety Company PeriGen, Inc., Acquired by Halma plc, a Global Group of Life Saving Technology Companies
PeriGen, Inc., the market leader in applying artificial intelligence (AI) to improve safety in childbirth, today announced it has been acquired by Halma plc. Based in the UK, Halma is a FTSE 100 global group of life-saving technology companies that provide innovative solutions to many of the key problems facing the world today – such as avoidable adverse events in childbirth. Halma’s ...
-
Thermo Fisher Scientific Announces New Human Plasma-Like Cell Culture Medium
Thermo Fisher Scientific today launched the new Gibco Human Plasma-like Medium (HPLM), the first cell culture medium on the market that mimics the metabolic profile of human plasma that is designed to provide researchers with a realistic view of cell growth within the human body. Gibco HPLM contains the same salt concentrations found in human plasma, as well as the same concentrations of over 60 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you